At a time when large-scale human genome analysis was not yet common, the Tohoku Medical Megabank Organization (ToMMo) launched its genome cohort study. After 10 years of operating this ambitious ...
This third of five exclusive episodes explores how clinicians can navigate newly approved MASH therapies -- resmetirom (Rezdiffra) and semaglutide (Wegovy) -- and how to tailor treatment choices based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback